GB2469754A - Sub-lingual drug delivery system using a neutral oil - Google Patents
Sub-lingual drug delivery system using a neutral oil Download PDFInfo
- Publication number
- GB2469754A GB2469754A GB1006818A GB201006818A GB2469754A GB 2469754 A GB2469754 A GB 2469754A GB 1006818 A GB1006818 A GB 1006818A GB 201006818 A GB201006818 A GB 201006818A GB 2469754 A GB2469754 A GB 2469754A
- Authority
- GB
- United Kingdom
- Prior art keywords
- eur
- oil
- composition according
- miglyol
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000007935 neutral effect Effects 0.000 title claims abstract description 15
- 238000012377 drug delivery Methods 0.000 title description 10
- 239000000203 mixture Substances 0.000 claims abstract description 90
- 239000003814 drug Substances 0.000 claims abstract description 75
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims abstract description 7
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical group [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 claims abstract description 3
- 229960000981 artemether Drugs 0.000 claims description 58
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 claims description 58
- 239000007921 spray Substances 0.000 claims description 45
- 239000003921 oil Substances 0.000 claims description 30
- 235000019198 oils Nutrition 0.000 claims description 30
- 239000002253 acid Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 150000003626 triacylglycerols Chemical class 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000000341 volatile oil Substances 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 6
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical class CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 claims description 6
- 229960002428 fentanyl Drugs 0.000 claims description 6
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000021323 fish oil Nutrition 0.000 claims description 6
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 6
- 239000003240 coconut oil Substances 0.000 claims description 5
- 235000019864 coconut oil Nutrition 0.000 claims description 5
- 239000010685 fatty oil Substances 0.000 claims description 5
- 125000005456 glyceride group Chemical group 0.000 claims description 5
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical class CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000012716 cod liver oil Nutrition 0.000 claims description 4
- 239000003026 cod liver oil Substances 0.000 claims description 4
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 4
- 239000010514 hydrogenated cottonseed oil Substances 0.000 claims description 4
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000003346 palm kernel oil Substances 0.000 claims description 4
- 235000019865 palm kernel oil Nutrition 0.000 claims description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 235000013311 vegetables Nutrition 0.000 claims description 4
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims description 3
- 229960001391 alfentanil Drugs 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 229960002970 artemotil Drugs 0.000 claims description 3
- NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 claims description 3
- 239000006184 cosolvent Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims description 3
- 229960004739 sufentanil Drugs 0.000 claims description 3
- -1 without limitation Chemical compound 0.000 claims description 3
- KRWBMXNBYQFMLZ-HOWIICQTSA-N (6e,10e,14e,18e,22e)-3,7,11,15,19,23,27-heptamethyloctacosa-6,10,14,18,22,26-hexaen-1-ol Chemical compound OCCC(C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C KRWBMXNBYQFMLZ-HOWIICQTSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims description 2
- 229960004991 artesunate Drugs 0.000 claims description 2
- YDSDEBIZUNNPOB-UHFFFAOYSA-N carfentanil Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 claims description 2
- 229950004689 carfentanil Drugs 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- PWEOPMBMTXREGV-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O PWEOPMBMTXREGV-UHFFFAOYSA-N 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 claims description 2
- 229950010274 lofentanil Drugs 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims description 2
- 229960003912 probucol Drugs 0.000 claims description 2
- 239000010464 refined olive oil Substances 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 238000009472 formulation Methods 0.000 description 32
- 230000008859 change Effects 0.000 description 28
- 229940079593 drug Drugs 0.000 description 23
- 239000003826 tablet Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 20
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 19
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 19
- 229940041616 menthol Drugs 0.000 description 19
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 14
- 229960004436 budesonide Drugs 0.000 description 14
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 13
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 13
- 238000003760 magnetic stirring Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 229960000991 ketoprofen Drugs 0.000 description 10
- 229960003088 loratadine Drugs 0.000 description 10
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- DQCKKXVULJGBQN-UWFFTQNDSA-N (4r,4as,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound C([C@@]12[C@@]3(O)CCC(=O)C1OC=1C(O)=CC=C(C2=1)C[C@]31[H])CN1CC1CC1 DQCKKXVULJGBQN-UWFFTQNDSA-N 0.000 description 9
- BJDCWCLMFKKGEE-HVDUHBCDSA-N Dihydroartemesinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(O)[C@@H]4C BJDCWCLMFKKGEE-HVDUHBCDSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 9
- 210000004877 mucosa Anatomy 0.000 description 7
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 229960002521 artenimol Drugs 0.000 description 6
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 description 6
- 229930016266 dihydroartemisinin Natural products 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 5
- 229960003022 amoxicillin Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000010579 first pass effect Methods 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 5
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 4
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 4
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 4
- 229960001736 buprenorphine Drugs 0.000 description 4
- 229960000520 diphenhydramine Drugs 0.000 description 4
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 4
- 229960000805 nalbuphine Drugs 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 229960004380 tramadol Drugs 0.000 description 4
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 4
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 3
- 229960004752 ketorolac Drugs 0.000 description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 3
- 229960001627 lamivudine Drugs 0.000 description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 3
- 229960003987 melatonin Drugs 0.000 description 3
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 3
- 229960004127 naloxone Drugs 0.000 description 3
- 229960005343 ondansetron Drugs 0.000 description 3
- 239000007935 oral tablet Substances 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 229960003310 sildenafil Drugs 0.000 description 3
- 229960002639 sildenafil citrate Drugs 0.000 description 3
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 3
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- 229960002555 zidovudine Drugs 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- PIFPCDRPHCQLSJ-WYIJOVFWSA-N 4,8,12,15,19-Docosapentaenoic acid Chemical compound CC\C=C\CC\C=C\C\C=C\CC\C=C\CC\C=C\CCC(O)=O PIFPCDRPHCQLSJ-WYIJOVFWSA-N 0.000 description 2
- OQOCQFSPEWCSDO-JLNKQSITSA-N 6Z,9Z,12Z,15Z,18Z-Heneicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O OQOCQFSPEWCSDO-JLNKQSITSA-N 0.000 description 2
- 241000276694 Carangidae Species 0.000 description 2
- PIFPCDRPHCQLSJ-UHFFFAOYSA-N Clupanodonic acid Natural products CCC=CCCC=CCC=CCCC=CCCC=CCCC(O)=O PIFPCDRPHCQLSJ-UHFFFAOYSA-N 0.000 description 2
- 241000555825 Clupeidae Species 0.000 description 2
- 241000167554 Engraulidae Species 0.000 description 2
- 235000019501 Lemon oil Nutrition 0.000 description 2
- 241000277350 Osmeridae Species 0.000 description 2
- 241000269821 Scombridae Species 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- HQPCSDADVLFHHO-LTKCOYKYSA-N all-cis-8,11,14,17-icosatetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HQPCSDADVLFHHO-LTKCOYKYSA-N 0.000 description 2
- JIWBIWFOSCKQMA-LTKCOYKYSA-N all-cis-octadeca-6,9,12,15-tetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O JIWBIWFOSCKQMA-LTKCOYKYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 229960004191 artemisinin Drugs 0.000 description 2
- 229930101531 artemisinin Natural products 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000010634 clove oil Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000010501 lemon oil Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 235000021290 n-3 DPA Nutrition 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 210000004258 portal system Anatomy 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 150000005691 triesters Chemical class 0.000 description 2
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- UETXPGADPCBQFT-UHFFFAOYSA-N 2,2-diphenyl-4-piperidin-1-ylbutanamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N)CCN1CCCCC1 UETXPGADPCBQFT-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241001660853 Ammodytidae Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000737241 Cocos Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 240000003133 Elaeis guineensis Species 0.000 description 1
- 235000001950 Elaeis guineensis Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- PPKXEPBICJTCRU-UHFFFAOYSA-N [2-hydroxy-2-(3-methoxyphenyl)cyclohexyl]methyl-dimethylazanium;chloride Chemical compound Cl.COC1=CC=CC(C2(O)C(CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 150000001226 dihydroartemisinin methyl ether derivatives Chemical class 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 235000020988 fatty fish Nutrition 0.000 description 1
- 229950010801 fenpipramide Drugs 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000002643 mouth floor Anatomy 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 229940051877 other opioids in atc Drugs 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- IHEHEFLXQFOQJO-UHFFFAOYSA-N piritramide Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 IHEHEFLXQFOQJO-UHFFFAOYSA-N 0.000 description 1
- 229960001286 piritramide Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960001402 tilidine Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
Abstract
A pharmaceutical composition for the sublingual delivery of medicaments comprising a neutral oil and a medicament soluble in said oil, providing that said medicament is not nitroglycerine or an artemesinin as defined therein. Also provided are delivery devices adapted for sublingual delivery of such compositions.
Description
DRUG DELIVERY
Field of the Invention
The invention relates to improved methods of delivery for medicaments, and to devices for drug delivery.
Background
The development of drug delivery routes remains an important element in the progress of the pharmaceutical sciences. Once an active compound has been identified, the design of delivery mechanisms must overcome challenges of transporting the medicament to the required site of action in the body whilst addressing issues including shelf stability, bioavailability, toxicity, and patient compliance. All of these challenges must be overcome to achieve the desired therapeutic effect. Amongst the drug delivery options, oral administration is by far the most common route, with other options including injection, topical, inhalation and transmucosal administration.
The oral delivery route faces perhaps the most challenging route for a pharmaceutical to reach the final site of action: The composition must survive the acidic and enzymatically-active environment of the stomach; if not absorbed in the stomach, the medicament must survive the action of bile salts and ftirther intestinal and bacterial enzymatic action within the intestinal tract, be able to cross from the lumen of the gut to the intestinal wall for absorption, and then survive the degradation processes of the liver following transport by the hepatic portal system, often resulting in poor availability due to the first pass effect.
Furthermore, many bioactive compounds elicit autoinduction of enzymes (e.g. in the hepatic system) that lead to increasing breakdown the drugs before they reach the systemic circulation, leading to a decrease of bioavailability of the molecules over time during a medicament administration regime. Despite these challenges, the oral route of drug administration remains the most common.
It is among the objectives of the present invention to attempt a solution to these problems.
Summary of the Invention
Accordingly, the invention provides a pharmaceutical composition for the sublingual delivery of a medicament comprising: a neutral oil; and a medicament soluble in said oil; wherein said medicament is in solution in said oil at a concentration providing a required dose in a volume of no more than lml of composition; providing that said medicament is not nitroglycerine.
The requirement for a composition for sublingual drug delivery is very different than that for oral drug delivery. Oral drug delivery requires adsorption of the drug from the gastrointestinal tract for which the drug is ideally soluble in the aqueous solutions found there. However, for sublingual drug delivery the product needs to be lipophilic to be adsorbed from the sublingual region of the body. Thus, formulations having a hydrophilic nature of this patent would not result in good adsorption. Such formulations are at risk of being washed down into the gastrointestinal tract without being adsorbed. Many of the drugs that may be used for sublingual delivery in this way are not absorbed from the gastrointestinal tract, and might lead to undesirable side-effects.
Particular medicaments envisaged include especially opioids such as fentanyl and buprenorphine, pharmaceutically acceptable salts thereof, analogues thereof or derivatives thereof. Other opioids envisaged include: alfentanil, sufentanil, butorphanol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphbne, propoxyphene, tramadol, fenpipramide,, pentazocine, piritramide, tilidine, tramadol, pharmaceutically acceptable salts thereof, or derivatives thereof, and the like.
Preferably, said medicament is in solution in said oil at a concentration providing a required dose of medicament in a volume of no more than 500microlitres of composition; more preferably in a volume of no more than 200microlitres of composition, and most preferably in a volume of no more than lOOmicrolitres of composition.
The use of such pharmaceutical compositions for delivery of medicaments by the sublingual route is appropriate, therefore, for those medicaments that have a suitably high solubility in neutral oils such that a required dose (e.g. an effective dose for a required pharmaceutical action) may be dissolved in a relatively small volume of composition, as above. This is particularly important, as the inventors have found that the sublingual delivery route offers (for many medicaments) substantial and hitherto unappreciated benefits over other administration routes. It is particularly beneficial over the oral route in which a medicament is often degraded by the various enzymatic and other processes in action in the gut, and leads to absorption by the hepatic route, which can lead to significant malabsorption as a result of the first pass effect" in the liver. As a result, orally-dosed medicaments are often given in greater concentration that would be required if they were well-absorbed and could escape the first-pass effect. As a consequence, unwanted side-effects might be experienced. In order to avoid oral absorption, the medicament is therefore delivered in a small volume, enough to coat the sublingual mucosa and to reduce the likelihood that any composition may be swallowed. The skilled addressee will be readily able to determine whether a chosen medicament has sufficient solubility, and examples are given below to show how this might be done.
The invention is especially concerned with compositions for the delivery of medicaments by the sublingual route for systemic treatment of an individual, rather than for medicaments for use as a topical treatment.
A further preferred feature is that the medicament is stable in the composition, both with respect to physicochemical aspects such as remaining in solution and in terms of chemical (including biochemical) degradation of the medicament over time. It is particularly preferred, therefore that the medicament is stable within the composition, to pharmaceutically-acceptable limits over a period of at least one month, preferably 6 months and most preferably for a year.
Preferably, said neutral oil comprises a glyceride, and more preferably a triglyceride.
In especially preferred embodiments said triglyceride comprises miglyol, and especially a miglyol selected from the group comprising: miglyol 810; miglyol 812; miglyol 818; miglyol 829; and miglyol 840.
Also in especially preferred embodiments said neutral oil comprises an oil selected from the group comprising: Refined Maize Oil (Ph Eur); Virgin Castor Oil (Ph Eur); Refined Olive Oil (Ph Eur) and Refined Rapeseed Oil (Ph Eur).
Also in especially preferred embodiments said neutral oil comprises an oil selected from the group comprising: Glycerol mono-oleates (Ph Eur); Linoleoyl Macrogolglycerides (Ph Eur); Oleoyl Macrogolglycerides (Ph Eur); Vegetable Fatty Oils (Ph Eur); rich in triglycerides, Medium Chain Triglycerides (Ph Eur); Coconut Oil (Ph Eur); Fractionated Palm Kernel Oil (Ph Eur); Hydrogenated Cottonseed Oil (Ph Eur); Omega-3-Marine Triglycerides (Ph Eur); Fish Oil, Rich in Omega-3 -Acids (Ph Eur); Cod Liver Oil (Ph Eur); Diglycerides; Monoglycerides; and Diglycerol.
Also in especially preferred embodiments said neutral oil comprises derivates or partial glycerides of an oil selected from the group comprising: Glycerol mono-oleates (Ph Eur); Linoleoyl Macrogolglycerides (Ph Eur); Oleoyl Macrogolglycerides (Ph Fur); Vegetable Fatty Oils (Ph Eur); rich in triglycerides, Medium Chain Triglycerides (Ph Eur); Coconut Oil (Ph Eur); Fractionated Palm Kernel Oil (Ph Eur); Hydrogenated Cottonseed Oil (Ph Eur); Omega-3-Marine Triglycerides (Ph Eur); Fish Oil, Rich in Omega-3-Acids (Ph Eur); Cod Liver Oil (Ph Eur); Diglycerides; Monoglycerides; and Diglycerol.
Medium chain length triglycerides are defined in the European Pharmacopoeia Monograph 0868, as: A mixture of triglycerides of saturated fatty acids, mainly of caprylic acid (octanoic acid, C8H1602) and of capric acid (decanoic acid, C10H2002). Medium-chain triglycerides are obtained from the oil extracted from the hard, dried fraction of the endosperm of Cocos nucifera L. or from the dried endosperm of Elaeis guineensis Jacq. When Medium-chain Triglycerides are prepared from the endosperm of Cocos nucfera L., the title Fractionated Coconut Oil may be used. Medium chain length triglycerides have a minimum 95.0 per cent of saturated fatty acids with 8 and 10 carbon atoms. Further chemical and physical properties are described in the European Pharmacopoeia Monograph 0868, and equivalent documents.
Omega-3-marine triglycerides are defined in the European Pharmacopoeia Monograph 0868 as mixture of mono-, di-and triesters of omega-3 acids with glycerol containing mainly triesters and obtained either by esterification of concentrated and purified omega-3 acids with glycerol or by transesterification of the omega-3 acid ethyl esters with glycerol.
The origin of the omega-3 acids is the body oil from fatty fish species coming from families like Engraulidae, Carangidae, Clupeidae, Osmeridae, Salmonidae and Scombridae. The omega-3 acids are identified as the following acids: alpha-linolenic acid (C18:3 n-3), moroctic acid (C18:4 n-3), eicosatetraenoic acid (C20:4 n-3), timnodonic (eicosapentaenoic) acid (C20:5 n-3; EPA), heneicosapentaenoic acid (C21:5 n-3), clupanodonic acid (C22:5 n-3) and cervonic (docosahexaenoic) acid (C22:6 n-3; DHA).
The sum of the contents of the omega-3 acids EPA and DHA, expressed as triglycerides is a minimum of 45.0 per cent, and the total omega-3 acids, expressed as triglycerides is a minimum of 60.0 per cent. Tocopherol may be added as an antioxidant.
Fish oil, rich in omega-3-acids is also defined in the European Pharmacopeia as purified, winterised and deodorised fatty oil obtained from fish of the families Engraulidae, Carangidae, Clupeidae, Osmeridae, Scombridae and Ammodytidae. The omega-3 acids are defined as the following acids: alpha-linolenic acid (C18:3 n-3), moroctic acid (C18:4 n-3), eicosatetraenoic acid (C20:4 n-3), timnodonic (eicosapentaenoic) acid (C20:5 n-3; EPA), heneicosapentaenoic acid (C21:5 n-3), clupanodonic acid (C22:5 n-3) and cervonic (docosahexaenoic) acid (C22:6 n-3; DHA).
The content of the Fish oil, rich in omega-3-acids is as follows: EPA, expressed as triglycerides: minimum 13.0 per cent, DHA, expressed as triglycerides: minimum 9.0 per cent, Total omega-3-acids, expressed as triglycerides: minimum 28.0 per cent.
In preferred embodiments any of said compositions, the compositions consist essentially of said neutral oil; and a medicament soluble in said oil.
In alternative embodiments of the above compositions, it is preferred that said composition further comprises a co-solvent selected from the group comprising: ethanol; isopropanol; propylene glycol; and polyethylene glycol.
In preferred embodiments any of said compositions, the compositions further comprise an excipient selected from the group comprising: an antioxidant; a preservative; a mucosal penetration enhancer, and a flavouring. Preferably, said flavouring or mucosal penetration enhancer comprises an essential oil such as menthol, vanillin or orange oil, lemon oil, clove oil, peppermint oil, spearmint oil. The inventors have found that the addition of such an essential oils surprisingly has three benefits: (1) the essential oils act as penetration enhancers, improving the rate and extent of uptake of such medicaments by the sublingual mucosa; (2) the essential oils, in many cases, act as co-solvents thereby increasing the solubility of medicaments; and (3) the essential oils provide a flavour component, giving organoleptic feedback to a user of the medicament, to confirm that is has been successfully delivered.
In preferred embodiments of any individual such composition, it is preferred that said medicament is not fentanyl, derivatives thereof such as sufentanil, carfentanil, lofentanil, alfentanil, or the like, and pharmaceutically acceptable salts thereof.
Also in preferred embodiments of any individual such composition, it is preferred that said medicarnent is not an artemesinin (including, without limitation, artemether, arteether and artesunate).
Also in preferred embodiments of any individual such composition, it is preferred that said medicarnent is not dihydropolyprenol (especially dihydroheptaprenol), probucol or tacrolimus.
Also in preferred embodiments of any individual such composition, it is preferred that said medicarnent is not a benzodiazepine.
In some conditions responsive to treatment with compositions or medicaments disclosed herein, patients may exhibit mucusitis and a dry mouth, especially when taking opioids.
The inventors have found that miglyol may be used as the sole solvent for the active compounds (with the exception of buprenorphine, which requires the use of ethanol as a co-colvent); this allows formulations to exclude ethanol and other alcohols as a co-solvent, which is particularly beneficial, as alcoholic preparations are particularly irritating to a dry mouth, or to patients having mucusitis and may cause discomfort or pain to the patient. Accordingly, in preferred embodiments of compositions disclosed herein, the composition is substantially, or preferably entirely free of ethanol and more preferably substantially, or preferably entirely free of other alcohols. Formulations such as this have an additional benefit that they may be used in cultural or religious contexts where alcohol intake is not permitted.
Additionally, the additional of alcohols to such lipophilic compositions has the effect of reducing the particle size of droplets (by surface tension and viscosity effects) when the compositions are delivered in the form of a spray. This can lead to the formation of droplets less than 2Otm, or even less than 1Otm, which can allow droplets to reach the lungs, which is undesirable. Furthermore, alcohols can have the effect of "closing down" the mucosa, thereby having a deleterious effect on absorption of the medicament.
Also in embodiments of any individual such composition, it is preferred that said composition has less than 20%(w/w), more preferably less than 1O%(w/w); more preferably still less than 5%(w/w); and most preferably less than 1 %(w/w) of surfactant.
In especially preferred embodiments, the composition is essentially free of surfactant. A key feature of the success of sublingual delivery is the provision of an essentially hydrophobic (lipophilic) composition; this leads to the composition remaining on the sublingual mucosa for absorption by that route. If surfactants are present within the composition, there is more likelihood that the composition will be able to mix with the essentially aqueous saliva in the mouth, leading to increased possibility that the composition will be moved away from the sublingual mucosa and, in extremis, swallowed by a user, thereby leading to oral rather than sublingual dosing.
Also included within the scope of the invention is a delivery device adapted to deliver successive doses of a composition according to any preceding claim, said doses comprising liquid droplets having a mean diameter of at least about 10 microns.
Preferably the compositions of the present invention are delivered as liquid droplets having a mean diameter of at least about 20 microns, more preferably a mean diameter of from about 20 to about 200 microns. Most preferably the formulations are delivered as liquid droplets have a size distribution of from about 5 microns to about 500 microns, preferably from about 10 microns to about 200 microns, preferably from about 20 microns to about 100 microns, more preferably from about 30 microns to about 70 microns.
Choice of these droplet sizes ensures that the spray is prevented from passing into the lungs.
It is particularly preferred that each individual or successive dose has a volume of less than 1000 microlitres. The use of small dose volumes reduces the likelihood that the composition will be swallowed, or spat out, by the patient. The likelihood is reduced further by use of smaller volumes (especially in the paediatric context or for nasal delivery) and so in further preferred embodiments, each successive dose has a volume of less than 600 microlitres; less than 400 microlitres; less than 200 microlitres; or even less than 100 microlitres. Smaller volumes are especially preferred for paediatric use.
Preferably, the delivery devices according to these aspects comprise a spray, and especially a pump spray. The use of a pump spray increases the area of mucosa to which the composition is applied, thereby increasing absorption and minimising the likelihood that the medicament is swallowed.
Description of Preferred Embodiments
The inventors have found that the use of sublingual delivery of medicaments is more broadly useful in overcoming the problems of drug delivery described above than has hitherto been recognised. The sublingual venous bed drains into the systematic circulation rather than the hepatic circulation, and so the problems of the first pass effect are removed. Furthermore, the bypassing of the hepatic portal system during drug uptake prevents the autoinduction that, for many medicaments, leads to reduction of bioavailability of drugs on successive doses. The use of a sublingual delivery route also means that medicaments may be delivered, avoiding the oral route, by non-trained personnel, in contrast to the alternative of intravenous injection that might be used to avoid the first-pass effect. Additionally, some drugs are not able to be formulated for intravenous injection. Additional benefits of sublingual delivery are that, by careful choice of excipients and droplet sizes, accidental delivery of drug by the oral route can be avoided, thereby preventing the unwanted complications of the oral delivery route.
Whilst some sublingual formulations have been used, these are often formulated using propellants and irritant excipients such as alcohols. For some patients, e.g. those who might have sensitive mucosa as a symptom of their condition, these excipients are unwelcome. In some preferred embodiments, therefore, formulations specifically exclude propellants and alcoholic excipients.
By way of non-limiting example, the following formulations of oil-soluble medicaments are proposed:
Example A: Nicotine
_______ _____ _____ _____ % (wiw) _____ _____ _____ Nicotine 1.06 1.06 1.06 1.06 1.06 1.06 1.06 Clove oil -1.06 1.07 1.06 1.06 1.06 1.06 BHT* --0.11 0.26 0.53 0.80 1.06 Miglyol 98.94 97.88 97.76 97.62 97.35 97.08 96.82 *Butylated hydroxy toluene Example B: Buprenorphine ______________ % (wiw) Buprenorphine base 1.1 4.4 8.4 Ethanol abs. 22.7 21.4 20.8 Miglyol 76.2 74.2 70.8
Example C: Fentanyl
______ ____ ____ ____ ____ % (wiw) ____ ___ ____ ____ Fentanyl Base 0.06 0.06 0.06 0.06 0.06 0.23 0.23 0.23 0.23 0.23 propyl parabens --0.11 0.21 0.42 --0.11 0.21 0.43 Orange oil -0.85 0.85 0.85 0.86 -0.85 0.85 0.85 0.86 miglyol 99.94 99.09 98.96 98.99 98.66 99.77 89.92 98.81 98.71 98.48 Additional excipients found by the inventors to be readily soluble in miglyol, and therefore of us in formulation of the present invention include: Flavourings: Orange oil; Lemon oil; Aniseed; Peppermint; and Menthol Preservatives: Propyl parabens and Butyl parabens Antioxidants: Butylated Hydroxy Toluene; Butylated Hydroxy Anisole and alpha tocopherol It has been thought that oil-based excipients can lead to low absorption of medicaments.
International Patent Application W0200708743 1 teaches that "... studies also showed that fentanyl base formulation containing Miglyol had very low permeability". In contrast to these findings, the inventors have found that the use of oil-based excipients as recited herein, for oil-soluble drugs, surprisingly leads to highly efficient uptake of the medicaments.
As an example, the inventors have carried out confidential trials of sublingual uptake of the artemesinin arteether, described in co-pending International Patent Application PCT/GB2008/050999, and reproduced here: Trials were carried out on healthy male adult human volunteers (16 subjects per cohort), and subject to normal ethical approval. Three single-dose regimes according to the present invention were studied, and compared to a regime using oral-dosed tablets, as follows: Sub-Lingual Spray Regimes Spray formulations of artemether were prepared as detailed above, and administered, on a single occasion, to a group of volunteers by the sublingual route. A number of successive actuations of the spray were administered, as shown in Table 6, below.
Table 6-Dosage Regime for Single Dose Study Sublingual Spray Formulation Dose per Number of Total Doge Test Formulation Actuation (mg) Actuations (mg)
Ti AsTable3 3 5 15
T2 AsTable3 3 10 30
T3 AsTable4 6 5 30
Reference Oral Dose As a reference, a fourth group of volunteers were administered tablets containing artemether, on a single occasion, as shown in Table 7, below.
Table 7-Dosage Regime for Single Dose Study Oral Tablet Formulation Dose per Tablet Number of Total Doge Test Formulation (mg) Tablets (mg)
T4 Tablet 10 3 30
Following administration of each dosage regime, blood samples were taken from the subjects, and plasma concentrations of artemether and its immediate metabolite dihydroartemesinin were determined, in order to compare bioavailability by the two routes.
Figures 1-6 show mean plasma concentration of artemether following two comparison dose regimes. Figures 7-12 show the corresponding mean plasma concentration of dihydroartemesinin.
Figures 1 and 7 compare regimes Ti (open squares) and T4 (closed circles): 15mg artemether via 5 sublingual spray doses vs. 30mg artemether via tablet.
Figures 2 and 8 compare regimes T2 (open squares) and T4 (closed circles): 30mg artemether via 10 sublingual spray doses vs. 30mg artemether via tablet.
Figures 3 and 9 compare regimes T3 (open squares) and T4 (closed circles): 30mg artemether via 5 sublingual spray doses vs. 30mg artemether via tablet.
Figures 4 and 10 compare regimes Ti (open squares) and T2 (closed circles): 15mg artemether via 5 sublingual spray doses vs. 30mg artemether via 10 sublingual spray doses.
Figures 5 and ii compare regimes T2 (open squares) and T3 (closed circles): 30mg artemether via 10 sublingual spray doses vs. 30mg artemether via 5 sublingual spray doses.
Figures 6 and 12 compare regimes Ti (open squares) and T3 (closed circles): 15mg artemether via 5 sublingual spray doses vs. 30mg artemether via 5 sublingual spray doses).
Pharmacokinetic data for each of the four dosage regimes are given in Tables 8-11, below: Table 8. Test Group Ti Single sublingual administration of i5mg Artemether sublingual spray.
3mg per actuation Plasma Artemether Plasma Dihydroartemesinin (n=16) (n=16) Pharmacokinetic Parameters ________________________ (mean �SD) (mean �SD) AUC012 (ng.hImL) 25.85�13 29.63 � 11.58 Cmax(ng/mL) 16.11 � 8.69 18.29 �7.52 Tmax (h) 1.70 � 0.68 1.83 � 0.68 t�(h) 0.72�0.30 ________________________ ______________________ 1.11�0.40 ______________________ CL/F (ng/h) 0.74 � 0.46 0.54 � 0.15 V/F (L) 0.68 � 0.33 0.51 � 0.16 * Key: AUC012 (ng.hlmL) Area under the concentration curve between 0-12 h. Cmax (ngi'mL) Maximum observed plasma concentration Tmax (h) Time of observed maximum plasma concentration ty2 (h) Elimination half-life X (h') Elimination rate constant CL/F (ng/h) Apparent clearance rate V/F (L) Apparent volume of distribution Table 9: Test Group T2 Single sublingual administration of3Omg Artemether sublingual spray: 3mg per actuation Plasma Artemether Plasma Dihydroartemesinin (n=16) (n=16) Pharmacokinetic Parameters ________________________ (mean �SD) (mean �SD) AUC012 (ng.hImL) 76.60 � 43.12 99.51 � 50.33 Cmax(ng/mL) 32.12� 16.39 44.11 �28.48 Tmax(h) 1.73�0.82 2.10�1.17 t�(h) 1.39�0.49 ________________________ 2 (h1) 0.56 � 0.20 ___________________________ CL/F (ng/h) 0.56 � 0.37 0.36 � 0.13 V/F (L) 1.00 � 0.55 0.72 � 0.36
Key as Table 8
Table 10. Test Group T3 Single sublingual administration of3omg Artemether sublingual spray.
6mg per actuation Plasma Artemether Plasma Dihydroartemesinin (n=16) (n=16) Pharmacokitnetic Parameters ________________________ (mean �SD) (mean �SD) AUC012(ng.hImL) 71.11 �41.08 86.19 �27.68 Cmax (ng/mL) 35.24 � 23.91 41.14 � 16.45 Tmax(h) 1.67�0.77 1.88�0.74 t�(h) 1.40�0.59 ________________________ 2 (h1) 0.59 � 0.25 ___________________________ CL/F (ng/h) 0.63 � 0.49 0.39 � 0.15 V/F(L) 1.01�0.49 0.91�0.67
Key as Table 8
Table 11: Test Group T4 Single oral administration of3omg Arteinether Tablets
10mg per Tablet
Plasma Artemether Plasma Dihydroartemesinin (n=16) (n=16) Pharmacokinetic Parameters ________________________ (mean �SD) (mean �SD) AUC012 (ng.hImL) 34.59 � 21.01 38.49 � 12.38 Cmax(ng/mL) 10.12�7.19 10.99�4.39 Tmax(h) 1.02�0.86 1.39�0.88 t�(h) 3.44�4.26 _______________________ _______________________ 0.31�0.15 _______________________ CL/F(ng/h) 1.11�1.01 0.76�0.23 V/F (L) 3.90 � 2.90 2.36 � 1.26
Key as Table 8
From these preliminary results, it can be seen that comparison of the area under the plasma concentration curve during the 12 hours following the doses (AUC012), a well-accepted measure of absorption, shows significant and surprisingly higher absorption of artemether when administered sublingually as a spray formulation as disclosed herein by comparison to oral tablet dosing.
For comparison of bioavailability of artemether via the sublingual spray route described herein with administration by oral tablets, we have calculated the F-values, commonly used to compare two dose regimes, generally A and B, for the artemether data, as follows: F -AUCA doseB
A-B
AUCB doseA The results are as follows: FT1T4 = 1.67 � 0.60 (S.D.) FT2T4 = 2.24 � 0.92 (S.D.) FT3T4 = 2.09 � 0.69 (S.D.) This indicates that approximately between 1.7 and 2.2 times more artemether was absorbed when administered as a sublingual spray as described herein by comparison to oral administration by tablet, despite the oral dose being twice as large in the first instance. The indicative bioavailability by the sublingual route is therefore at least twice that by the oral route for equivalent doses.
Inspection of the data of Tables 8-11, and Figures 1-12 also confirms this general finding for the primary active metabolite of artemether (dihydroartemesinin).
Avoidance of Autoinduction It is known that both oral and rectal administration of artemesinins is associated with autoinduction of the drug metabolism in individuals (see e.g. Ashton M, Hai TN, Sy ND, Huong DX, Van Huong N, Nieu NT, Cong LD. "Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. ", Drug Metab Dispos. 1998; 26:25-7, and "Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model", Asimus and Gordi, Br. J Clin Pharmacol. 2007 June; 63(6): 758-762). As a result, systemically circulating artemesinin declines with each successive dose, thereby reducing the effectiveness of drug dosage regimes.
In confidential trials, the inventors have found that administration of artemesinins by the transmucosal sublingual route avoids such autoinduction, leading to consistent uptake and accumulating systemic concentration of the active drug metabo lite, dihydroartemesinin, thereby providing significant advantage in administration by the sublingual route. A similar avoidance of autoinduction is expected with delivery by the transmucosal buccal or nasal route.
In confidential trials, volunteers followed the following treatment: A single administration of 30mg artemether sublingual spray 6mg/actuation on days 1 and 5 following an overnight fast, and twice daily administrations of 30mg artemether sublingual spray 3mg/actuation on days 2, 3,and 4 following a morning or evening meal. Blood samples were collected for pharmacokinetic analysis at the following time points: Day 1: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,4, 6, 8, and 12 h after dosing.
Days 2, 3, and 4: pre morning dose and 0.5, 1, 2 and 4 h after morning dose and pre evening dose and 1 hour after evening dose.
DayS: Predose, 0.25,0.5,0.75,1,1.5,2,2.5,3,4,6,8, l2hand24hafterdosing.
Pharmacokinetic analysis of plasma dihydroartemesinin on days 1 and 5 revealed an effectively identical response, indicating the lack of autoinduction. Plasma concentration curves are shown in Figure 14.
Solubility of Medicaments By way of example, to show how the skilled addressee might determine whether such compositions are suitable for a given medicament, solubility tests have been carried out on a number of pharmaceutical actives as detailed below. All drugs were used at their lowest concentration as used in IV injections, with the exception of Amoxicillin and Diphenhydramine. Solutions were prepared in Miglyol 810.
Amoxicillin: 4g of Amoxicillin was weighed into a beaker and 50m1 of Miglyol was added. This was then diluted to lOOml with Miglyol. The pale yellow suspension was magnetically stirred but didn't dissolve. Amoxicillin appears not to be soluble in Miglyol.
However, the Amoxicillin used contained other excipients.
Budesonide: 50mg of Budesonide was weighed into a beaker and 50m1 of Miglyol was added. This was then diluted to lOOml with Miglyol. After extensive magnetic stirring a suspension was seen that did not dissipate upon further dilution and subsequent stirring.
After the addition of heat and menthol (to separate solutions) the Budesonide was seen to dissolve. Budesonide appears to be soluble with the addition of heat or menthol.
Diphenhydramine: 2.5g of Diphenhydramine was weighed into a beaker and 50m1 of Miglyol was added. After stirring, a further 150m1 of Miglyol was added. A pale white cloudy suspension was seen that became less cloudy upon magnetic stirring.
Diphenhydramine appears to be sparingly soluble in Miglyol.
Ketoprofen: ig of Ketoprofen was weighed into a beaker and 50m1 of Miglyol was added.
A cloudy off-white suspension was seen that did not lighten upon magnetic stirring.
Ketoprofen appears to be insoluble in Miglyol. (See below with respect to solubility enhancement.) Ketorolac: 75 0mg of Ketorolac was weighed into a beaker and 50m1 of Miglyol was added. After stirring, a further 50m1 of Miglyol was added. A Pale white, very cloudy suspension was seen that did not dissipate upon magnetic stirring. Ketorolac appears to be insoluble in Miglyol.
Lamivudine: 500mg of Lamivudine was weighed into a beaker and 50m1 of Miglyol was added. After extensive magnetic stirring a cloudy white suspension was seen that did not dissipate. Lamivudine appears to be insoluble in Miglyol.
Lidocaine Base: 1.25g of Lidocaine Base was weighed into a beaker and 50m1 of Miglyol was added. After magnetically stirring for approximately 15 minutes the solution became slightly less cloudy, and after a further 15 minutes stirring the solution became clear.
Lidocaine Base is readily soluble in Miglyol.
Loratadine: 500mg of Loratadine was weighed into a beaker and 50m1 of Miglyol was added. After magnetically stirring for 15 minutes a clear solution was observed.
Loratadine is readily soluble in Miglyol.
Melatonin: 3.75g of Melatonin was weighed into a beaker and 50m1 of Miglyol added.
This was then further diluted to lOOml then 200m1 with Miglyol. After magnetic stirring, a thick pale yellow suspension was seen. After initially diluting to lOOml then to 200m1 the solution did not change. Melatonin appears to be insoluble in Miglyol.
Nalbuphine HC1: 5 00mg of Nalbuphine HC1 was weighed into a beaker and 50m1 of Miglyol was added. The suspension was magnetically stirred for approximately 40 minutes but no change was seen. Nalbuphine HC1 is not soluble in Miglyol.
Naloxone: 100mg of Naloxone was weighed into beaker and 50m1 of Miglyol was added.
Upon magnetically stirring a cloudy solution was observed but no particulate matter was seen on the bottom. Naloxone appears to be sparingly soluble in Miglyol.
Naltrexone Base: ig of Naltrexone Base was weighed into a beaker and 50m1 of Miglyol was added. This was further diluted to lOOml with Miglyol. For the first dilution a cloudy suspension was seen that did not dissipate. Upon the addition of 50m1 of Miglyol and further stirring the suspension appeared to lighten. Naltrexone Base appears to be sparingly soluble. It may dissolve completely at a lower concentration. (See below with respect to solubility enhancement.) Ondansetron HC1: ig of Ondansetron HC1 was weighed into a beaker and 50m1 of Miglyol was added. This was further diluted to lOOml with Miglyol. A cloudy suspension was seen that did not dissolve upon magnetic stirring or the addition of 50m1 of Miglyol. Ondansetron HC1 appears to be insoluble.
Prilocaine Base: 1.25g of Prilocaine base was weighed into a beaker and 50m1 of Miglyol was added. Upon magnetically stirring for 5 minutes a clear solution was seen with slight particulate matter resting on the bottom that dissolved after standing.
Prilocaine Base appears to be readily soluble in Miglyol.
Salbutamol Sulphate: 200mg of Salbutamol Sulphate was weighed into a beaker and 5 Oml of Miglyo 1 was added. After extensive magnetic stirring a cloudy white suspension was seen. Salbutamol Sulphate appears to be insoluble in Miglyol.
Sildenafil Citrate: ig of Sildenafil Citrate was weighed into a beaker and lOml of Miglyol was added. This was further diluted to 50m1 with Miglyol. A dense white suspension was observed that did not dissipate upon magnetic stirring. Sildenafil Citrate appears to be insoluble in Miglyol.
Sildenafil Base: ig of Sildenafil Base was weighed into a beaker and lOml of Miglyol was added. This was further diluted to 50m1 with Miglyol. A dense white suspension was observed that did not dissipate upon magnetic stirring. Sildenafil Base appears to be insoluble in Miglyol.
Terbutaline Sulphate: 50mg of Terbutaline Sulphate was weighed into a beaker and 50m1 of Miglyol was added. A fine suspension was seen that did not dissipate upon magnetic stirring. Terbutaline Sulphate appears to be insoluble in Miglyol.
TramadolHCl: 2.5g of Tramadol HC1 was weighed into a beaker and 50m1 of Miglyol was added. A cloudy suspension was seen that did not dissipate upon magnetic stirring.
Tramadol HC1 appears to be insoluble in Miglyol.
Zidovudine: 500mg of Zidovudine was weighed into a beaker and 50m1 of Miglyol was added. A cloudy white suspension was seen that did not dissipate upon stirring.
Zidovudine appears to be insoluble in Miglyol.
Solubility Enhancement by Essential Oils Further tests established the solubility enhancement effect of heat and, surprisingly, the additional of an essential oil; menthol was used in this example.
Ketoprofen: 50mg of Ketoprofen was weighed into a beaker and 50m1 of Miglyol was added. The samples dissolved with heat or menthol, thought much faster with heat.
Ketoprofen is soluble in Miglyol with the addition of heat or menthol.
Naltrexone Base: 100mg of Naltrexone Base was weighed into a beaker and 50m1 of Miglyol was added. The samples dissolved with heat or menthol, thought much faster with heat. Naltrexone Base appears to be soluble with the addition of heat or menthol.
For the medicaments tested above that showed good solubility in Miglyol (Lidocaine Base, Prilocaine Base, Loratadine and Budesonide), further studies were carried out to assess the solubility limits and to provide example formulations to guide the skilled addressee in applying the invention to formulation for other medicaments: Lidocaine Base: An approximate solubility limit was found to be approximately 1 4Omg.mL'. Three formulations were made and are shown in Table 10.1.
Prilocaine Base: An approximate solubility limit was found to be approximately 137mg.mL'. Three formulations were made and are shown in Table 10.2.
Loratadine: An approximate solubility limit was found to be approximately 2Omg.mL'.
Three formulations were made and are shown in Table 10.3.
Table 10.1 Final
Lidocaine Base Concentration of Formulation (g) Menthol (g) Miglyol (ml) drug (mg.mL') 1 2.5053 0.600 100 25.1 2 5.0008 0.590 100 50.0 3 10.0152 0.605 100 100.2
Table 10.2
Prilocaine Base Final Concentration of Formulation (g) Miglyol (ml) drug (mg.mL') 1 2.5086 100 25.1 2 5.0111 100 50.0 3 10.0971 100 101.0
Table 10.3
Final Concentration Formulation Loratadine (g) Miglyol (ml) of drug(mg.mL') 1 1.0397 100 10.4 2 2.0176 100 20.2 Further Formulation work Further work was undertaken on drugs thought previously insoluble in Miglyol in light of Budesonide appearing to be insoluble in Miglyol but upon further formulation dissolving with heat or menthol (see below). Example formulations are given below in Tables 10.4 and 10.5.
Table 10.4 Final
Concentration of Formulation Ketoprofen (g) Menthol (g) Miglyol (ml) drug (mg.mL') 1 0.0520 0.335 50 1.04 2 0.0500 -50 1.00
Table 10.5 Final
Naltrexone Base Concentration of Formulation (g) Menthol (g) Miglyol (ml) drug (mg.mL') 1 0.1041 0.340 50 2.08 2 0.1061 -50 2.12 Budesonide: A solubility limit was not established for this drug because it appeared not to be compatible with Miglyol. However, after using heat and menthol (separately) the Budesonide appeared to dissolve. Two formulations are shown in Table 10.6
Table 10.6
Miglyol Final Concentration Formulation Budesonide (g) Menthol (g) (ml) of drug (mg.mL') 1 0.0507 0.605 50 1.01 2 0.0503 -50 1.01 These results demonstrate the ability of essential oils to act as solubilising agents.
Stability of Medicaments To assess the stability of example formulations, four of the medicaments (Lidocaine, Prilocaine, Laratadine and Budesonide) were filled into serum bottles, sealed and subjected to stability tests at a range of temperatures and relative humidity. The results are given in Tables 11.1 and 11.2.
Table 11.1
Drug Stability Time-point Observations ______________________ Conditions _______________ _____________________ Lidocaine Base 5°C, 25°C/6O°/ 24 Hours No colour change, and (2Smg/ml) RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Lidocaine Base 5°C, 25°C/6O°/ 24 Hours No colour change, and (SOmg/ml) RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Lidocaine Base 5°C, 25°C/6O°/ 24 Hours No colour change, and (lOOmg/ml) RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Prilocaine Base 5°C, 25°C/6O°/ 24 Hours No colour change, and (25mg/ml) RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Prilocaine Base 5°C, 25°C/6O°/ 24 Hours No colour change, and (SOmg/ml) RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Prilocaine Base 5°C, 25°C/6O°/ 24 Hours No colour change, and (lOOmg/ml) RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Loratadine (lOmg/ml) 5°C, 25°C/6O°/ 24 Hours No colour change, and RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Loratadine (2Omg/ml) 5°C, 25°C/6O°/ 24 Hours No colour change, and RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Budesonide + Heat 5°C,30°C/65% RH 24 Hours No colour change, and (lmg/ml) and 40°C/75% RH no apparent solubility issues Budesonide + Menthol 5°C,30°C/65% RH 24 Hours No colour change, and (lmg/ml) and 40°C/75% RH no apparent solubility issues The samples were also checked at 4 days and 5 days. No colour change or solubility issues were apparent.
Table 11.2
Drug Stability Time-point Observations ______________________ Conditions _______________ _____________________ Lidocaine Base 5°C, 25°C/6O°/ 1 Month No colour change, and (2Smg/ml) RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Lidocaine Base 5°C, 25°C/6O°/ 1 Month No colour change, and (SOmg/ml) RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Lidocaine Base 5°C, 25°C/6O°/ 1 Month No colour change, and (lOOmg/ml) RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Prilocaine Base 5°C, 25°C/6O°/ 1 Month No colour change, and (25mg/ml) RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Prilocaine Base 5°C, 25°C/6O°/ 1 Month No colour change, and (SOmg/ml) RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Prilocaine Base 5°C, 25°C/6O°/ 1 Month No colour change, and (lOOmg/ml) RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Loratadine (lOmg/ml) 5°C, 25°C/6O°/ 1 Month No colour change, and RH, 30°C/65% RH no apparent solubility ______________________ and 40°C/75% RH _______________ issues Loratadine (2Omg/ml) 5°C, 25°C/6O°/ 1 Month Small particulate RH, 30°C/65% RH matter adhering to the and 40°C/75% RH bottom of the Serum bottle. No colour _____________________ _________________ _______________ change.
Budesonide + Heat 5°C,30°C/65% RH 1 Month No colour change, and (lmg/ml) and 40°C/75% RH no apparent solubility issues Budesonide + Menthol 5°C,30°C/65% RH 1 Month No colour change, and (lmg/ml) and 40°C/75% RH no apparent solubility issues Further stability tests were carried out with Ketoprofen and Naltrexone, and the results presented in Table 11.3.
Table 11.3
Drug Stability Time-point Observations ______________________ Conditions _______________ _____________________ Ketoprofen (lmg/ml) 5°C, 30°C/65% 24 Hours No colour change, and + Menthol RH and 40°C/75% no apparent solubility RH issues Ketoprofen (lmg/ml) 5°C, 30°C/65% 24 Hours No colour change, and + Heat RH and 40°C/75% no apparent solubility RH issues Naltrexone Base 5°C, 30°C/65% 24 Hours No colour change, and (2mg/ml) RH and 40°C/75% no apparent solubility + Menthol RH ______________ issues Naltrexone Base 5°C, 30°C/65% 24 Hours No colour change, and (2mg/ml) RH and 40°C/75% no apparent solubility + Heat RH issues These samples were also checked after S and 6 days and no colour change or solubility issues were noted.
Supplementary Figure Captions Figure 1: Plot of mean plasma Artemether concentration vs time with standard deviation following a single sublingual administration of 15mg Artemether Sublingual Spray 3mg/actuation (Ti) and single oral administration of 30mg Artemether Tablets 10 mg/tablet (14). Mean � SD (. = reference, T4, n = test, Ti) Figure 2: Plot of mean plasma Artemether concentration vs time with standard deviation following a single sublingual administration of 30mg Artemether Sublingual Spray 3mg/actuation (T2) and single oral administration of 30mg Artemether Tablets 10 mg/tablet (14). Mean � SD (. = reference, T4, n = test, T2) Figure 3: Plot of mean plasma Artemether concentration vs time with standard deviation following a single sublingual administration of 30mg Artemether Sublingual Spray 6mg/actuation (T3) versus single oral administration of 30mg Artemether Tablets 10 mg/tablet (14). Mean � SD (. = reference, T4, n = test, T3) Figure 4: Plot of mean plasma artemether concentration vs time with standard deviation following a single sublingual administration of 15mg Artemether Sublingual Spray 3mg/actuation (Ti) versus single sublingual administration of 30mg Arternether Sublingual Spray 3mg/actuation (T2). Mean � SD (. = reference, T2, n = test, Ti) Figure 5: Plot of mean plasma Artemether concentration vs time with standard deviation following a single sublingual administration of 30mg Artemether Sublingual Spray 3mg/actuation (T2) versus single sublingual administration of 30mg Arternether Sublingual Spray 6mg/actuation (T3). Mean � SD (. = reference, T3, n = test, T2) Figure 6: Plot of mean plasma Artemether concentration vs time with standard deviation following a single sublingual administration of 15mg Artemether Sublingual Spray 3mg/actuation (Ti) versus single sublingual administration of 30mg Arternether Sublingual Spray 6mg/actuation (T3). Mean � SD (. = reference, T3, n = test, Ti) Figure 7: Plot of mean plasma Dihydroartemisinin concentration vs time with standard deviation following a single sublingual administration of 15mg Artemether Sublingual Spray 3mg/actuation (Ti) and single oral administration of 30mg Artemether Tablets 10 mg/tablet (T4). Mean � SD (. = reference, T4, = test, Ti) Figure 8: Plot of mean plasma Dihydroartemisinin concentration vs time with standard deviation following a single sublingual administration of 30mg Artemether Sublingual Spray 3mg/actuation (T2) and single oral administration of 30mg Artemether Tablets 10 mg/tablet (T4). Mean � SD (. = reference, T4, = test, T2) Figure 9: Plot of mean plasma Dihydroartemisinin concentration vs time with standard deviation following a single' sublingual administration of 30mg Artemether Sublingual Spray 6mg/actuation (T3) versus single oral administration of 30mg Artemether Tablets mg/tablet (T4). Mean � SD (.= reference, T4, = test, T3) Figure 10: Plot of mean plasma Dihydroartemisinin concentration vs time with standard deviation following a single sublingual administration of 15mg Artemether Sublingual Spray 3mg/actuation (Ti) versus single sublingual administration of 30mg Artemether Sublingual Spray 3mg/actuation (T2). Mean � SD (. = reference, T2, = test, Ti) Figure ii: Plot of mean plasma Dihydroartemisinin concentration vs time with standard deviation following a single sublingual administration of 30mg Artemether Sublingual Spray 3mg/actuation (T2) versus single sublingual administration of 30mg Artemether Sublingual Spray 6mg/actuation (T3). Mean � SD (. = reference, T3, = test, T2) Figure 12: Plot of mean plasma Dihydroartemisinin concentration vs time with standard deviation following a single sublingual administration of 15mg Artemether Sublingual Spray 3mg/actuation (Ti) versus single sublingual administration of 30mg Artemether Sublingual Spray 6mg/actuation (T3). Mean � SD (. = reference, T3, = test, Ti)
Claims (26)
- CLAIMS1. A pharmaceutical composition for the sublingual delivery of a medicarnent comprising: a neutral oil; and a medicament soluble in said oil; wherein said medicament is in solution in said oil at a concentration providing a required dose in a volume of no more than lml of composition; providing that said medicament is not nitroglycerine, and is not an artemesinin (including, without limitation, artemether, arteether and artesunate).
- 2. A composition according to claim 1 wherein said neutral oil comprises a glyceride.
- 3. A composition according to claim 2 wherein said glyceride comprises a triglyceride.
- 4. A composition according to claim 3 wherein said triglyceride comprises miglyol.
- 5. A composition according to claim 4 wherein said miglyol comprises miglyol selected from the group comprising: miglyol 810; miglyol 812; miglyol 818; miglyol 829; and miglyol 840.
- 6. A composition according to claim 1 wherein said neutral oil comprises an oil selected from the group comprising: Refined Maize Oil (Ph Eur); Virgin Castor Oil (Ph Eur); Refined Olive Oil (Ph Eur) and Refined Rapeseed Oil (Ph Eur).
- 7. A composition according to claim 1 wherein said neutral oil comprises an oil selected from the group comprising: Glycerol mono-oleates (Ph Eur); Linoleoyl Macrogolglycerides (Ph Eur); Oleoyl Macrogolglycerides (Ph Eur); Vegetable Fatty Oils (Ph Eur); rich in triglycerides Medium Chain Triglycerides (Ph Eur); Coconut Oil (Ph Eur); Fractionated Palm Kernel Oil (Ph Eur); Hydrogenated Cottonseed Oil (Ph Eur); Omega-3 -Marine Triglycerides (Ph Eur); Fish Oil, Rich in Omega-3-Acids (Ph Eur); Cod Liver Oil (Ph Eur); Diglycerides; Monoglycerides; Diglycerol.
- 8. A composition according to claim 1 wherein said neutral oil comprises derivates or partial glycerides of an oil selected from the group comprising: Glycerol mono-oleates (Ph Eur); Linoleoyl Macrogolglycerides (Ph Eur); Oleoyl Macrogolglycerides (Ph Eur); Vegetable Fatty Oils (Ph Eur); rich in triglycerides Medium Chain Triglycerides (Ph Eur); Coconut Oil (Ph Eur); Fractionated Palm Kernel Oil (Ph Eur); Hydrogenated Cottonseed Oil (Ph Eur); Omega-3 -Marine Triglycerides (Ph Eur); Fish Oil, Rich in Omega-3-Acids (Ph Eur); Cod Liver Oil (Ph Eur); Diglycerides; Monoglycerides; Diglycerol.
- 9. A composition according to any preceding claim consisting essentially of said neutral oil; and a medicament soluble in said oil.
- 10. A composition according to any preceding claim, substantially free of ethanol.
- 11. A composition according to claim 10, substantially free of alcohols.
- 12. A composition according to any of claims 1 to 9, further comprising a co-solvent selected from the group comprising: ethanol; isopropanol; propylene glycol; polyethylene glycol.
- 13. A composition according to any preceding claim, further comprising an excipient selected from the group comprising: an antioxidant; a preservative; a mucosal penetration enhancer; a flavouring.
- 14. A composition according to claim 13 wherein said mucosal penetration enhancer comprises an essential oil.
- 15. A composition according to claim 13 wherein said flavouring comprises an essential oil.
- 16. A pharmaceutical composition according to any preceding claim providing that said medicament is not fentanyl, derivatives thereof such as sufentanil, carfentanil, lofentanil, alfentanil, or the like, and pharmaceutically acceptable salts thereof.
- 17. A pharmaceutical composition according to any preceding claim providing that said medicament is not dihydropolyprenol (especially dihydroheptaprenol), probucol or tacrolimus.
- 18. A pharmaceutical composition according to any preceding claim having less than 20% (w/w) of surfactant.
- 19. A pharmaceutical composition according to claim 18 having less than 10%(w/w) of surfactant.
- 20. A pharmaceutical composition according to claim 19 having less than 5%(w/w) of surfactant.
- 21. A pharmaceutical composition according to claim 20 having less than 1%(w/w) of surfactant.
- 22. A pharmaceutical composition according to claim 21 essentially free of surfactant.
- 23. A delivery device adapted to deliver successive doses of a composition according to any preceding claim, said doses comprising liquid droplets having a mean diameter of at least about 10 microns.
- 24. A delivery device according to claim 23 wherein said droplets have a mean diameter of at least about 20 microns.
- 25. A delivery device according to either of claims 23 and 24 wherein said droplets have a mean diameter of from about 20 to about 200 microns.
- 26. A delivery device according to any of claims 23 to 25 wherein said doses are delivered by a pump spray.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0906977A GB2469792A (en) | 2009-04-23 | 2009-04-23 | Oil-based pharmaceutical formulation for sublingual delivery |
PCT/GB2009/050416 WO2010122276A1 (en) | 2009-04-23 | 2009-04-23 | Drug delivery |
Publications (3)
Publication Number | Publication Date |
---|---|
GB201006818D0 GB201006818D0 (en) | 2010-06-09 |
GB2469754A true GB2469754A (en) | 2010-10-27 |
GB2469754B GB2469754B (en) | 2012-07-18 |
Family
ID=40774840
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0906977A Withdrawn GB2469792A (en) | 2009-04-23 | 2009-04-23 | Oil-based pharmaceutical formulation for sublingual delivery |
GB1006818.7A Expired - Fee Related GB2469754B (en) | 2009-04-23 | 2010-04-23 | Composition for use in the sublingual delivery of medicaments to humans |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0906977A Withdrawn GB2469792A (en) | 2009-04-23 | 2009-04-23 | Oil-based pharmaceutical formulation for sublingual delivery |
Country Status (1)
Country | Link |
---|---|
GB (2) | GB2469792A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2481619A (en) * | 2010-06-30 | 2012-01-04 | Londonpharma Ltd | Formulations and delivery devices for the sublingual administration of oipoids |
GB2534624A (en) * | 2014-08-21 | 2016-08-03 | Simon Corbitt Terence | Formulations for transmucosal delivery |
WO2018169497A1 (en) * | 2017-03-17 | 2018-09-20 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | Spray formulation comprising cholecalciferol (vitamin d3) with improved stability |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220312826A1 (en) * | 2021-04-06 | 2022-10-06 | Altria Client Services Llc | Liquid mixtures of triglyceride and liquid nicotine |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2380129A (en) * | 2001-02-14 | 2003-04-02 | Gw Pharma Ltd | Self-emulsifying pharmaceutical compositions |
US20050025716A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20070287755A1 (en) * | 2006-06-12 | 2007-12-13 | Rosario Ammirante | Orally administered compound for preventing neonatal hemorrhages, in a tardy form, caused by a K-vitamin dificiency |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993021909A1 (en) * | 1992-04-27 | 1993-11-11 | Vyrex Corporation | Improved delivery formulation for lipophilic drugs |
US20020099067A1 (en) * | 1993-07-08 | 2002-07-25 | Ulrich Posanski | Pharmaceutical compositions for sparingly soluble therapeutic agents |
US5955098A (en) * | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
WO1998025599A1 (en) * | 1996-12-12 | 1998-06-18 | Pharmacia & Upjohn Company | An oil composition of dihydropolyprenols |
SE9703458D0 (en) * | 1997-09-25 | 1997-09-25 | Pharmacia & Upjohn Ab | Nicotine compositions and methods of formulation thereof |
US20040136913A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing sumatriptan |
IT1302682B1 (en) * | 1998-10-16 | 2000-09-29 | Formenti Farmaceutici Spa | ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING BUPRENORPHINE |
US6617356B2 (en) * | 2000-01-03 | 2003-09-09 | Naturally Scientific Inc | Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements |
MXPA06014397A (en) * | 2004-06-17 | 2007-02-15 | Galderma Sa | Composition in spray form comprising a combination of a corticoid and a vitamin d derivative in an oily phase. |
GB0513984D0 (en) * | 2005-07-07 | 2005-08-17 | Teva Pharma | Dosage form |
BRPI0707235B8 (en) * | 2006-01-25 | 2021-05-25 | Insys Therapeutics Inc | sublingual fentanyl formulation without propellant, and, unit dose device for sublingual administration of a sublingual fentanyl formulation |
GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
GB0720967D0 (en) * | 2007-10-25 | 2007-12-05 | Protophama Ltd | Anti-material pharmaceutical composition |
-
2009
- 2009-04-23 GB GB0906977A patent/GB2469792A/en not_active Withdrawn
-
2010
- 2010-04-23 GB GB1006818.7A patent/GB2469754B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050025716A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
GB2380129A (en) * | 2001-02-14 | 2003-04-02 | Gw Pharma Ltd | Self-emulsifying pharmaceutical compositions |
US20070287755A1 (en) * | 2006-06-12 | 2007-12-13 | Rosario Ammirante | Orally administered compound for preventing neonatal hemorrhages, in a tardy form, caused by a K-vitamin dificiency |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2481619A (en) * | 2010-06-30 | 2012-01-04 | Londonpharma Ltd | Formulations and delivery devices for the sublingual administration of oipoids |
GB2481619B (en) * | 2010-06-30 | 2012-06-20 | Londonpharma Ltd | Formulations and delivery devices for the sublingual administration of opioids |
GB2534624A (en) * | 2014-08-21 | 2016-08-03 | Simon Corbitt Terence | Formulations for transmucosal delivery |
WO2018169497A1 (en) * | 2017-03-17 | 2018-09-20 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | Spray formulation comprising cholecalciferol (vitamin d3) with improved stability |
Also Published As
Publication number | Publication date |
---|---|
GB2469792A (en) | 2010-11-03 |
GB201006818D0 (en) | 2010-06-09 |
GB0906977D0 (en) | 2009-06-03 |
GB2469754B (en) | 2012-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120058158A1 (en) | Sublingual Pharmaceutical Composition Comprising a Neutral Oil | |
US20190290576A1 (en) | Anti-malarial pharmaceutical composition | |
US20190142737A1 (en) | Sublingual spray formulation comprising dihydroartemesinin | |
GB2469754A (en) | Sub-lingual drug delivery system using a neutral oil | |
WO2010122276A1 (en) | Drug delivery | |
WO2010122275A1 (en) | Pharmaceutical preparation | |
AU2013201643B2 (en) | Anti-malarial pharmaceutical composition | |
GB2469791A (en) | Lipophilic compositions comprising an artemisinin derivative and their therapeutic uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
COOA | Change in applicant's name or ownership of the application |
Owner name: LONDONPHARMA LIMITED Free format text: FORMER OWNER: CALVIN JOHN ROSS |
|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20210423 |
|
S28 | Restoration of ceased patents (sect. 28/pat. act 1977) |
Free format text: APPLICATION FILED |
|
S28 | Restoration of ceased patents (sect. 28/pat. act 1977) |
Free format text: RESTORATION ALLOWED Effective date: 20220511 |
|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20230423 |